The GT20029 tincture, a topical androgenreceptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
Clascoterone shows promising results for hair regrowth in men with androgenetic alopecia, with potential FDA approval by 2026. It acts as a topical androgenreceptor blocker, offering a new treatment option with minimal side effects compared to existing treatments like finasteride.
Experimenting with trestolone as a treatment for hair loss in an attempt to avoid DHT-related treatments such as finasteride and dutasteride, and discussing the potential effects of its receptor selectivity on the androgenreceptors in the scalp.
Hair loss recovery using estrogen and anti-androgen treatment for 18 months showed significant improvement. However, results vary and alternative treatments like RU58841 and Dutasteride may work without systemic feminization.